The Indian pharma distribution market is a ₹5 lakh crore opportunity by FY28. Most investors are chasing listed retail pharmacy chains. But there’s a less-noticed digital-first player quietly building the supply chain backbone behind 62,000 retail pharmacies — while also running a B2C online pharmacy app.
That company is Health X Platform Limited (NSE: HEALTHX), formerly Sastasundar Ventures.
Here are my notes, but before that:
Help us grow: If you think our stock recommendations could add value to your friends, relatives, or acquaintances, we’d appreciate you spreading the word about Katalyst Wealth.
Latest Stock recommendations for Premium Members:
- Alpha & Alpha+ (Released: 2nd Jun ’26) A first-mover in a $7 billion global recycling opportunity — with proprietary technology that addresses a problem no one has cleanly solved yet. (opens in new tab)Read the full recommendation →
- Alpha+ (Released: 11th May ’26) A special situation with a 1–2 month holding period. ~14% upside from recommended levels (assuming full acceptance), and the stock needs to fall 10%+ before investors start losing money. (opens in new tab)Access this idea by signing up →
- Insider Bets (Released: 19th Apr ’26) A rare setup: promoter buying more via preferential allotment, valuations under 10x earnings and 1x book, and 20%+ earnings CAGR. Three green flags in one stock. (opens in new tab)See the full report by signing up →
Health X Platform – Notes from Q4 FY26 concall
The Business in Brief
HealthX operates two platforms:
- SastaSundar App (B2C): Online pharmacy + diagnostics + wellness for consumers
- Retailer Shakti (B2B): Pharma supply chain platform for retail pharmacies
Both run on a shared fulfilment infrastructure — currently 2.5 lakh sq. ft. of warehousing, scaling to 8+ lakh sq. ft. by FY27-28.
Q4 FY26 Financials (Consolidated)
- Revenue from Operations: ₹378 Cr (Q4) | ₹1,306 Cr (FY26)
- Revenue growth: 34% YoY (Q4) | 20% YoY (FY26)
- Gross Profit: ₹27.5 Cr (Q4) | ₹97.5 Cr (FY26)
- Gross Margin: 7.3% (Q4) | 7.5% (FY26) — up from 6.5% in FY25
- EBITDA Loss: ₹20.8 Cr (Q4) | ₹65.5 Cr (FY26) — improved from ₹78.9 Cr in FY25
- PAT: Near breakeven at -₹1.4 Cr for FY26 vs. -₹133.5 Cr in FY25
Revenue split in Q4 FY26: Retailer Shakti — ₹310.5 Cr | SastaSundar — ₹44.5 Cr
Capital Efficiency — The Standout Metric
Management’s framing: Total capital raised + cost of capital (9% post-tax XIRR) = ₹783 Cr. Net of buybacks, treasury, and net assets — the capital actually deployed to build the operating business (IPR) works out to ₹119 Cr. Working capital is 18 days / 5% of revenue against ₹1,300+ Cr in annual revenue.
Key Business Updates from the Call
- Retailer Shakti’s scale: Serving 62,000 retail pharmacies, 700+ pharma company partnerships, 78% CAGR since inception in 2019.
- JITO — Generic Medicine Brand: Launched in Q4, pricing 60% below branded alternatives. Early traction at ~₹30 lakh/month in just month two. Two-thirds from Retailer Shakti, one-third from SastaSundar. Margins are 30-40%+. Still very early.
- FY27 Guidance: Management expects Q1 FY27 to be the best quarter in company history at ~₹400 Cr — implying annualised run rate of ₹1,600-1,700 Cr.
- FY30 Target: ₹6,000 Cr revenue — ₹4,000 Cr from Retailer Shakti, ₹2,000 Cr from SastaSundar. EBITDA target of 5% at that scale, PAT of 4%.
- Warehousing Capex: ₹234 Cr total — ₹134 Cr via bank loans, ₹100 Cr from treasury. New FCs in Udaipur, Lucknow, Patna, and Guwahati.
- Hospital Channel: New initiative — targeting emergency/backup stock fulfilment for hospitals on a cash-and-carry basis. No credit extended.
- AI Products: RetailAir (B2B automated filling tool) and a counselling tool for the B2C app are ready but rollout is being held back 6 months pending market readiness assessment.
- Non-medicine revenue: Currently ~2% of Retailer Shakti sales. Target to take it to 10% within a year. Personal care and beauty to be added by Dec 2026.
Key Risks to Track
- Still EBITDA negative; profitability dependent on scale and JITO margin contribution
- Large capex cycle (₹234 Cr) ahead — execution risk on new FCs
- Treasury management involves AIFs, unquoted shares, structured deals — management acknowledges taking measured risk for 10-12% yield vs. 7-8% in conventional instruments
- SastaSundar B2C growth was muted in FY26 during transition to JITO stores
- AI product rollout timelines are uncertain
As always, this is not a stock recommendation — This note is for informational purposes only and not a buy/sell recommendation. Please do your own due diligence before investing.
Hope you found the blog post useful and it added value to your investment decisions. Sign up for more interesting stock ideas and industry notes.
Not a research subscriber yet?
If you found this useful, our paid members get full research reports with entry levels, financial models, and entry-exit updates on stocks like these.
(opens in new tab)Explore Katalyst Wealth subscriptions →
Disclaimer: This is not a recommendation to buy/sell any of the stocks mentioned above. The securities quoted are for illustration only and are not recommendatory.
Ekansh Mittal
Research Analyst
SEBI Research Analyst Registration No. INH100001690
Research Analyst Details
Name: Ekansh Mittal Email Id: (opens in new tab)[email protected] Ph: +91 727 5050062
Details of Associate: Not Applicable
Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.
Disclaimer: (opens in new tab)http://www.
Registered Address – 7, Panch Ratan, 7/128, Swaroop Nagar, Kanpur – 208002
Place of Business – 205, Ratan Floor, 113/120, Swaroop Nagar, Kanpur – 208002
Compliance Officer/Grievance Redressal – Mr. Ekansh Mittal, +91-9818866676, (opens in new tab)info@
“Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors”.
“Investment in securities market are subject to market risks. Read all the related documents carefully before investing.”
The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision
This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.
We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.
Use of Artificial Intelligence: RA may infrequently use Artificial Intelligence (AI) tools like chatgpt, notebooklm, etc. in its research services to enhance the quality and efficiency of the recommendations provided to clients. The tools are primarily used for data collection and generating con-call summaries for the purpose of research.
In accordance with Regulation 24(7) of the SEBI (Research Analyst) Regulations, 2014: We take full responsibility for the security, confidentiality, and integrity of client data used in conjunction with AI tools and we ensure compliance with applicable laws regarding the use of AI tools.
Disclaimer: You can access it here – (opens in new tab)LINK
Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – No
Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No
Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No
Whether it or its associates have received any compensation from the subject company in the past twelve months – No
Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No
Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No
Whether the research analyst has served as an officer, director or employee of the subject company – No
Whether the research analyst or research entity has been engaged in market making activity for the subject company – No